2. Gene
  3. C9 - complement component 9 Gene

C9 - complement component 9 Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Mus musculus

基因 ID: 12279 | 基因类型: protein coding

关于 C9

功能概要

Predicted to be involved in blood coagulation; cell killing; and protein homooligomerization. Predicted to act upstream of or within complement activation, alternative pathway; complement activation, classical pathway; and cytolysis. Predicted to be located in extracellular space and plasma membrane. Predicted to be part of membrane attack complex. Is expressed in several structures, including brain; endocrine gland; genitourinary system; liver; and submandibular gland. Human ortholog(s) of this gene implicated in age related macular degeneration 15 and complement component 9 deficiency. Orthologous to human C9 (complement C9). [provided by Alliance of Genome Resources, Apr 2022]

C9 基因产物(3)

mRNA Protein Name
NM_001368420.1 NP_001355349.1 complement component C9 isoform 3 precursor
NM_001368421.1 NP_001355350.1 complement component C9 isoform 2
NM_013485.3 NP_038513.2 complement component C9 isoform 1 precursor
蛋白主名 其他名称

complement component C9

相关产品

Approval
生物活性分子 (8)
目录号 产品名 作用方式
纯度 是否罕见病
HY-17356 Fenofibrate 99.97% 是
HY-N6972 Cepharanthine 99.87% 是
HY-B0258 Gemfibrozil 99.91% 是
HY-B1218 Sulfaphenazole Inhibitor 99.85% 否
HY-100386 Ticlopidine Inhibitor 99.74% 否
HY-13463 Avatrombopag Agonist 99.83% 是
HY-13463B Avatrombopag hydrochloride Agonist 97.05% 是
HY-13463A Avatrombopag maleate 99.88% 是
Clinical Phase
生物活性分子 (8)
目录号 产品名 作用方式
纯度 Phase
HY-132581 Tadnersen Inhibitor 90.06% Phase 3
HY-N1201 Apigenin 99.22% Phase 2
HY-106379 Lurosetron Antagonist / Phase 2
HY-15565 APD668 99.73% Phase 1
HY-15566 APD597 Agonist 99.97% Phase 1
HY-12946 BI 653048 Inhibitor 99.84% Phase 1
HY-114415 AWZ1066S Inhibitor 98.64% Phase 1
HY-12946A BI 653048 phosphate Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (184)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-N0904 Ginsenoside C-K Inhibitor 99.92% 否
HY-N0043 Ginsenoside Rd Inhibitor 99.88% 否
HY-N0893 Tetrahydrocurcumin 98.96% 否
HY-15550S 4'-Hydroxy diclofenac-d4 98.92% 否
HY-103661 BI-6C9 Inhibitor 98.47% 否
HY-15550 4'-Hydroxy diclofenac 99.70% 否
HY-W013268 (S)-(+)-N-3-Benzylnirvanol Inhibitor 99.82% 否
HY-N0920 Dihydrokavain Inhibitor 99.94% 否
HY-148907 CS640 Inhibitor 96.13% 否
HY-117026 LKY-047 Inhibitor 99.94% 否
HY-153898 rTRD01 Ligand 99.10% 否
HY-100738 Ubiquitin Isopeptidase Inhibitor I, G5 Inducer 98.0% 否
HY-117389 Homocarbonyltopsentin 99.88% 否
HY-N1446S Oleic acid-13C 99.95% 否
HY-N0911 Rehmannioside A 99.96% 否
HY-139345 (S,R,S)-AHPC-CO-C9-acid Chemical 95.00% 否
HY-N0215S10 L-Phenylalanine-13C9 Antagonist 98.09% 否
HY-114759 MS-PPOH Inhibitor 99.05% 否
HY-100641 4-Hydroxytolbutamide 99.69% 否
HY-14362 GSK-25 Inhibitor 99.68% 否
HY-148822 Nampt activator-2 Activator 98.80% 否
HY-157581 MS39 Degrader 99.89% 否
HY-B0158S7 Cytidine-13C9 Chemical ≥95.0% 否
HY-N0473S3 L-Tyrosine-13C9 99.81% 否
HY-D1422 ER Thermo Yellow 96.91% 否
HY-100641S 4-Hydroxytolbutamide-d9 99.29% 否
HY-42034 Hydroquinine 99.84% 否
HY-N0688 Linderane Inhibitor 99.61% 否
HY-N1050 Zederone Inhibitor 99.61% 否
HY-132581A Tadnersen sodium Inhibitor 90.06% 否
HY-17356R Fenofibrate (Standard) 99.91% 否
HY-N0215S11 L-Phenylalanine-13C9,15N Antagonist 99.52% 否
HY-N1201R Apigenin (Standard) 98.82% 否
HY-144652 IDO1-IN-19 Inhibitor 98.82% 否
HY-18063 ML252 Inhibitor 99.9% 否
HY-128859 EMT inhibitor-2 Inhibitor 98.83% 否
HY-113359AS2 Uridine 5'-diphosphate-13C9,15N2 dilithium Agonist 99.5% 否
HY-125818S3 Cytidine-5'-triphosphate-13C9 dilithium 99.0% 否
HY-B0258R Gemfibrozil (Standard) 99.90% 否
HY-W751165 Uridine-13C9,15N2 ≥99.0% 否
HY-116862 Dibenzylfluorescein 99.54% 否
HY-W013175S2 Uridine 5'-monophosphate-13C9,15N2 disodium Activator ≥99.0% 否
HY-B0258S Gemfibrozil-d6 98.00% 否
HY-107372S2 Uridine triphosphate-13C9 dilithium 98.0% 否
HY-124352 2-Nonyl-3-hydroxy-4-quinolone ≥98.0% 否
HY-17356S Fenofibrate-d6 99.70% 否
HY-B1449S11 Uridine-13C9 99.00% 否
HY-N1201S Apigenin-d5 98.90% 否
HY-N7057S3 Nonanoic acid-d2 98.63% 否
HY-N8382 Chalepensin Inhibitor ≥98.0% 否
HY-W009162S5 Cytidine 5′-monophosphate-13C9,15N3 dilithium 99.80% 否
HY-Y0123S DL-Tyrosine-13C9,15N ≥98.0% 否
HY-N11222 Nonanoylcarnitine 99.87% 否
HY-W009216S1 2'-Deoxycytidine-5'-monophosphate-13C9,15N3 dilithium 99.80% 否
HY-101399S γ-Glu-(Phe-13C9,15N) / 否
HY-107372S Uridine triphosphate-13C9,15N2 sodium / 否
HY-131495 (S)-6-O-Desmethylnaproxen Inhibitor 95.73% 否
HY-D0184S3 2'-Deoxycytidine-13C9,15N3 99.00% 否
HY-N6023 Thermopsoside Inhibitor ≥98.0% 否
HY-U00048 Bucolome Inhibitor 98.93% 否
HY-101399SA γ-Glu-(Phe-13C9,15N) TFA / 否
HY-132581E Scrambled Tadnersen Control / 否
HY-15550S1 4'-Hydroxy diclofenac-13C6 / 否
HY-156159 Thalidomide-NH-C9-NH2 hydrochloride 99.85% 否
HY-159191S VQPGQN(Phe-13C9,15N)HMFTKEKLEEVIKDI TFA 95.41% 否
HY-W018801 5-Nitroisoquinoline 99.38% 否
HY-172177 ROCK/HDAC-IN-2 / 否
HY-A0070AS1 Liothyronine-13C9,15N / 否
HY-135390 Hydroxy desmethyl Bosentan / 否
HY-100386S Ticlopidine-d4 Inhibitor / 否
HY-101400S2 Deoxycytidine triphosphate-13C9,15N3 dilithium Activator / 否
HY-101400S4 Deoxycytidine triphosphate-13C9 dilithium Activator / 否
HY-101981S3 Uridine 5'-monophosphate-13C9,15N2 dilithium Activator / 否
HY-101981S4 Uridine 5'-monophosphate-13C9 dilithium Activator / 否
HY-113359AS1 Uridine 5'-diphosphate-13C9 dilithium Agonist / 否
HY-113400S1 Cytidine diphosphate-13C9 dilithium / 否
HY-113400S2 Cytidine diphosphate-13C9,15N3 dilithium 99.7% 否
HY-113887 Prostaglandin F1β Agonist / 否
HY-113887A 11β-Prostaglandin F1β Control / 否
HY-116095 CypD-IN-5 Inhibitor / 否
HY-116601 6-Hydroxywarfarin / 否
HY-119996 AR-C141990 Inhibitor / 否
HY-132581C Scrambled Tadnersen sodium Control / 否
HY-13463BS Avatrombopag-d8 hydrochloride Agonist / 否
HY-138517 Thiol-C9-PEG7 / 否
HY-138526 Thiol-C9-PEG4-acid / 否
HY-138527 Thiol-C9-PEG4 / 否
HY-138528 Thiol-C9-PEG5-acid / 否
HY-138529 Thiol-C9-PEG5 / 否
HY-141547 Nav1.7-IN-8 Inhibitor / 否
HY-141878 di-Ellipticine-RIBOTAC Modulator / 否
HY-141913S 3-Chlorotyrosine-13C9, 15N hydrochloride / 否
HY-143906 URAT1 inhibitor 2 Inhibitor / 否
HY-145490 trans-Hydroxy Glimepiride / 否
HY-147807 HIV-1 inhibitor-40 Inhibitor / 否
HY-148597 FGFR-IN-10 Inhibitor / 否
HY-149866 HIV-1 inhibitor-58 Inhibitor / 否
HY-150710S Cytidine 5'-triphosphate-13C9,15N3 ammonium / 否
HY-151251 CYP2C9/CYP2C19-IN-1 Inhibitor / 否
HY-151253 CYP2C1/CYP2C19-IN-2 Inhibitor / 否
HY-153371 50-C2-C9-4tail / 否
HY-153970 URAT1 inhibitor 7 Inhibitor / 否
HY-155265 Pomalidomide-5-C9-NH2 hydrochloride 98.68% 否
HY-159143 BChE-IN-33 Inhibitor / 否
HY-160555 (S,R,S)-AHPC-CO-C9-NH2 / 否
HY-160555A (S,R,S)-AHPC-CO-C9-NH2 hydrochloride 98.79% 否
HY-161943 NEU3-IN-1 / 否
HY-163208 VH 032 amide-alkylC9-amine hydrochloride / 否
HY-163816 Antiproliferative agent-53-d3 Inhibitor / 否
HY-166934S Endosulfan-13C9 sulfate / 否
HY-167872 Bifeprofen Inhibitor / 否
HY-168235 (S,R,S)-AHPC-Me-amide-C9-acid Degrader / 否
HY-168277 5-Aminothalidomide-C9-Boc / 否
HY-169095 (S,R,S)-AHPC-Me-CO-C9-NH2 / 否
HY-171837 c9,t11,c15-CLNA Activator / 否
HY-172897 EGFR/DHFR-IN-2 / 否
HY-172902 RNA binder 1 / 否
HY-173032 VU6033685 Agonist / 否
HY-17356G Fenofibrate (GMP) / 否
HY-17356S1 Fenofibrate-d4 / 否
HY-176737 TGF-β1/Smad-IN-1 Inhibitor / 否
HY-177070 Angexostat Inhibitor / 否
HY-79131S1 Fmoc-Phe-OH-13C9,15N 99.33% 否
HY-B1422S 9-Aminoacridine-13C6 Inhibitor / 否
HY-D0184S5 2'-Deoxycytidine-13C9 96.8% 否
HY-N0043R Ginsenoside Rd (Standard) Inhibitor / 否
HY-N0215S9 L-Phenylalanine-13C9,15N,d8 Antagonist / 否
HY-N0893S Tetrahydrocurcumin-d6 / 否
HY-N0904R Ginsenoside C-K (Standard) Inhibitor / 否
HY-N1201S1 Apigenin-13C / 否
HY-P5538S EPYFGYSGAFK-13C9,15N3 TFA / 否
HY-P5947 Tat-HA-NR2B9c / 否
HY-RS00534 AKR1C1 Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS01759 C9 Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS01760 C9orf72 Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS01761 C9orf78 Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS03460 CYP2C9 Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-W008849S DMT-dC(bz) Phosphoramidite-13C9,15N3 / 否
HY-W009216S4 2'-Deoxycytidine-5'-monophosphate-13C9 dilithium 99.5% 否
HY-W011090S ((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate-13C9,15N3 sodium / 否
HY-W015007S Metyrosine-13C9,15N,d7 Inhibitor / 否
HY-W018386AS 3-​Bromo-​L-​tyrosine-13C9,15N TFA / 否
HY-W018386S1 3-​Bromo-​L-​tyrosine-13C9 / 否
HY-W042357S4 Ac-rC Phosphoramidite-13C9 / 否
HY-W042357S6 Ac-rC Phosphoramidite-13C9,15N3 / 否
HY-W048482S1 rU Phosphoramidite-13C9,15N2 / 否
HY-W048482S2 rU Phosphoramidite-13C9 / 否
HY-W127393 N-Nonanoyl-L-homoserine lactone / 否
HY-W753181 (S)-2-Hydroxy-3-phenylpropanoic acid-13C9 / 否
HY-113455S1 9(S)-HODE-13C18 Inducer / 否
HY-117160 4-trans-Hydroxy-glibenclamide Inhibitor / 否
HY-117925 Personalised postprandial-targeting Inhibitor / 否
HY-124209 9-keto Fluprostenol / 否
HY-124352S 2-Nonyl-3-hydroxy-4-quinolone-d4 / 否
HY-134999 10-Hydroxywarfarin Inhibitor / 否
HY-149566 Thalidomide-5-O-C9-NH2 hydrochloride 99.59% 否
HY-149572 Thalidomide-4-O-C9-NH2 hydrochloride / 否
HY-150712S Uridine triphosphate-13C9,15N2 dilithium / 否
HY-156133 Dihydrospinosyn A aglycone / 否
HY-164031 Cloperidone Inhibitor / 否
HY-169119 Antifungal agent 114 Inhibitor / 否
HY-169735 Aurora A inhibitor 4 Inhibitor / 否
HY-170367 Antimicrobial agent-35 Inhibitor / 否
HY-171836 c9,t11-CLA / 否
HY-172335 C9-200 / 否
HY-17356S2 Fenofibrate-13C6 / 否
HY-175169 Urease-IN-21 Inhibitor / 否
HY-18063A ML252 hydrochloride Inhibitor / 否
HY-B0158S5 Cytidine-13C9,15N3 / 否
HY-B0258S1 Gemfibrozil-d6-1 / 否
HY-N12962 11S(12R)-EET / 否
HY-N12962A 11R(12S)-EET / 否
HY-P0036S3 Octreotide-13C9,15N / 否
HY-RS17317 C9 Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS20470 Psma4 Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS21991 C9orf72 Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS23772 C9 Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W008016S Fmoc-Tyr(tBu)-OH-13C9,15N 98.8% 否
HY-W009162S1 Cytidine 5′-monophosphate-13C9 dilithium / 否
HY-W440809 Nonyl 8-bromooctanoate / 否
HY-W587878 Thujopsene / 否
HY-W770410 9-PAHSA-13C4 / 否
HY-W800740 Nonyl 6-bromohexanoate / 否
HY-113623 Pyrenophorol / 否
抗体抑制剂 (3)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99141 Anti-Mouse LAG-3 Antibody (C9B7W) Inhibitor 95.00% 否
HY-P990140 Anti-Rat β-2-Microglobulin Antibody (4C9) / 否
HY-P990204 Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens C9 NCBI NCBI:735
Macaca fascicularis C9 NCBI NCBI:102137382
Leporidae C9 NCBI
Rattus norvegicus C9 NCBI NCBI:117512
Macaca mulatta C9 NCBI NCBI:694223
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z